Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-09, Vol.13 (17), p.4455
Main Authors: Davey, Matthew G, Hynes, Sean O, Kerin, Michael J, Miller, Nicola, Lowery, Aoife J
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Biomarkers
Breast cancer
Cell cycle
Cell proliferation
Clinical medicine
Decision making
Epidermal growth factor
ErbB-2 protein
Estrogen receptors
Invasiveness
Ischemia
Mastectomy
Oncology
Progesterone
Proteins
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13174455